Related Experiment Video
Updated: May 27, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Responsiveness to P2Y12 receptor inhibitors
1Division of Cardiology, Federico II University, Naples, Italy.
Current Opinion in Cardiology
|December 2, 2011
Summary
Clopidogrel resistance, a variable response to this antiplatelet drug, is linked to increased cardiovascular events. Current platelet function tests lack standardization and do not reliably predict outcomes, making routine use not recommended.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Clinical Trials
Background:
- P2Y12 inhibitors like clopidogrel are crucial in managing cardiovascular diseases.
- Interindividual variability in patient response to clopidogrel necessitates understanding non-responsiveness.
- Genetic factors, such as CYP2C19 mutations, significantly influence clopidogrel metabolism and efficacy.
Purpose of the Study:
- To review the variability in patient responses to P2Y12 inhibitor agents.
- To examine the diagnostic tools available for assessing P2Y12 inhibitor responsiveness.
- To discuss the clinical implications of clopidogrel resistance.
Main Methods:
- Literature review of studies on P2Y12 inhibitor response variability.
- Analysis of current platelet function tests for assessing drug responsiveness.
- Evaluation of clinical trial data, including the GRAVITAS study.
Main Results:
- High interindividual variability in clopidogrel response exists, influenced by patient and drug-related factors.
- Mutations in CYP2C19 are associated with increased cardiovascular risk in non-responders.
- Current platelet function tests lack correlation with clinical outcomes and standardized methods for clinical practice.
Conclusions:
- Clopidogrel resistance is associated with a higher incidence of cardiovascular events.
- No uniform definition of 'non-responder' exists, and reducing platelet reactivity does not guarantee reduced events.
- Personalized antiplatelet therapy based on risk profile, not solely platelet function, is suggested pending further large-scale trials.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:25Dose-Response Relationship: Selectivity and Specificity
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:03Pharmacodynamic Responses: Different Types
Pharmacodynamics is the scientific study of a drug's biochemical or physiological influence on the body. It categorizes responses into continuous, discrete (or categorical), and time-to-event outcomes. Continuous responses yield numerical values within a certain range, such as blood pressure readings and blood glucose levels, gauging the efficacy of antihypertensive and antidiabetic drugs. Discrete responses can be binary, indicating whether a drug has an effect or not, or ordinal, exemplifying...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...